Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001104659-15-008723
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-02-11 12:32:53
Reporting Period:
2015-02-10
Filing Date:
2015-02-11
Accepted Time:
2015-02-11 12:32:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
890465 Nps Pharmaceuticals Inc NPSP Biological Products, (No Disgnostic Substances) (2836) 870439579
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1577637 E Susan Graf 550 Hills Drive
Bedminster NJ 07921
Vp, Corp Development & Strateg No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-02-10 6,711 $14.90 10,511 No 4 M Direct
Common Stock Disposition 2015-02-10 6,711 $45.87 3,800 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Options (right to buy) Disposition 2015-02-10 6,711 $0.00 6,711 $14.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
41,289 2023-06-17 No 4 M Direct
Footnotes
  1. On June 17, 2013, the reporting person received a grant of 48,000 stock options under NPS Pharmaceuticals Inc.'s amended and restated 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the date of grant and 6.25% every three months thereafter.